The PKCtheta kinase plays a critical role in T-cell receptor signaling and it is a highly relevant target for T-cell mediated inflammatory and autoimmune diseases e.g. ulcerative colitis (UC)and rheumatoid arthritis (RA). PKCtheta has garnered significant attention from the pharmaceutical industry and, using our drug discovery process, Aqilion is aiming for best-in-class PKCtheta inhibitors.

Aqilion has identified highly potent and selective PKCtheta inhibitors using advanced structure-based design. This has resulted in a unique set of structurally diverse molecules with excellent drug-like properties.